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Purpose: To compare intravitreal bevacizumab monotherapy with intravitreal dexameth-
asone delayed delivery system monotherapy for persistent diabetic macular edema.
Methods: Single-center, randomized, subject-masked study of eyes with persistent
diabetic macular edema, deﬁned as central subﬁeld thickness (CST) .340 mm despite $3
anti–vascular endothelial growth factors injections within 5 months. The intravitreal beva-
cizumab monotherapy (n = 23 eyes) and delayed delivery system monotherapy (n = 27
eyes) groups received treatments q1month and q3months, respectively.
Results: Baseline best-corrected visual acuity and CST were similar in the two groups.
At Month 7, the mean ﬁnal best-corrected visual acuity (mean ± SD) was 65 ± 16 letters
(mean Snellen visual acuity 20/50) and 64 ± 11 letters (20/50) (P = 0.619), the mean change
in best-corrected visual acuity was +5.6 ± 6.1 and +5.8 ± 7.6 letters (P = 0.785), the mean
ﬁnal CST was 471 ± 157 and 336 ± 89 mm (P = 0.001), and the mean change in CST was
213 ± 105 and 2122 ± 120 mm (P = 0.005) in the intravitreal bevacizumab monotherapy
and delayed delivery system monotherapy groups, respectively. The number of injections
was 7.0 ± 0.2 and 2.7 ± 0.5 (P , 0.001) in the 2 groups.
Conclusion: The two groups had similar best-corrected visual acuity gains. The delayed
delivery system monotherapy group achieved a signiﬁcantly greater reduction of CST
compared with the intravitreal bevacizumab monotherapy group, with a q3month interval of
treatment, and had no recurrent edema at any visit.
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Diabetes is the most common cause of new blindnessin the working-age adults aged 20 years to 74 years
in the United States.1 Approximately 1 in every 25 dia-
betic patients aged 40 years or older has diabetic macular
edema (DME) in at least one eye in the United States.2
Anti–vascular endothelial growth factor (anti-
VEGF) agents have become the new gold standard
for the treatment of DME after several randomized
controlled trials demonstrated their superiority over
laser photocoagulation.3–6 However, the DME control
with anti-VEGF agents is not without exception, and,
in fact, a signiﬁcant proportion of eyes continue to
have persistent DME despite treatment.
In DRCR protocol I, 40% of patients in the 2
ranibizumab groups had residual macular edema with
central subﬁeld thickness (CST) exceeding 250 mm
after 2 years despite strict adherence to study proto-
col.4 The RISE/RIDE combined data showed that in
ranibizumab-treated eyes, at least 26% have contin-
ued edema and approximately 74% of eyes have
angiographic leakage at 2 years.5 In DRCR Protocol
T, CST remained greater than 250 mm in 44% of
aﬂibercept-treated eyes, 64% of bevacizumab-
treated eyes, and 42% of ranibizumab-treated eyes
at 1 year.7 There is indirect evidence that such per-
sistent macular edema can cause permanent vision
loss, possibly related to prolonged disruption of ret-
inal architecture from the edema, producing irrevers-
ible retinal damage. In the 36-month results of RISE/
RIDE, patients who received monthly 0.5 mg
1986
ranibizumab after an initial 2 years of sham treatment
failed to achieve the same degree of visual improve-
ment as those patients who were treated continuously
with monthly 0.5 mg ranibizumab, despite having
a similar reduction in macular edema.8
Although no randomized studies were found that
evaluated patients with DME unresponsive to bevaci-
zumab, several nonrandomized prospective studies
have evaluated this question. The REEF study attemp-
ted to switch from one anti-VEGF agent to another and
showed ranibizumab to achieve visual and anatomical
improvements in some of the eyes with DME resistant
to bevacizumab therapy, but as expected, the control
was not universal.9 The use of laser to supplement
anti-VEGF therapies has been previously advocated
and studied. However, recent studies, including the
DRCR.net 3-year results and a 5-year multicenter ran-
domized controlled trial, established the lack of dis-
cernable visual acuity beneﬁt of the addition of laser to
anti-VEGF agents over the long term for DME con-
trol.10,11 Therefore, there is a need for a different agent
to treat this subset of eyes with persistent DME unre-
sponsive to anti-VEGF agents.
The dexamethasone implant (Ozurdex, Allergan, Inc.,
Irvine, CA) was approved by the US Food and Drug
Administration in September 2014 for the treatment of
DME. Our previous 12-month study comparing bev-
acizumab with dexamethasone combination therapy
versus bevacizumab monotherapy for diabetic eyes that
were partially responsive to anti-VEGF treatment
showed that macular edema reduction was signiﬁcantly
greater in the combination group versus the monother-
apy group (245 mm vs.230 mm, P = 0.03) and that the
visual acuity gain was similar in both groups (+5.4
letters vs. +4.9 letters, P = 0.75).12 Also, we learned
that the macular edema improvement did not last the
full 4 months interval of treatment used in that study,
and edema recurred to a signiﬁcant extent after 3
months.12 Therefore, if dexamethasone implant alone,
at q3month intervals, which seems to be the duration of
clinical efﬁcacy in patients with persistent DME, is
found to be equivalent to current anti-VEGF agents
such as bevacizumab (which is used q4weeks–
q6weeks) in treating persistent DME, then it would
imply signiﬁcantly fewer injections and possibly fewer
patient visits. Therefore, in this randomized study, we
directly compared bevacizumab monotherapy to dexa-
methasone monotherapy in the treatment of DME.
Methods
Study Design
This prospective, subject-masked, randomized, con-
trolled trial was conducted at a single site. The
institutional review board approved the study protocol
and each subject provided written informed consent
before enrollment. The study site complied with the
Health Insurance Portability and Accountability Act.
The study involved off-label use of intravitreal
bevacizumab for the treatment of DME.
Participants
Eligible patients were recruited from the practice
of the principal investigator. Included were patients
with diabetes mellitus Type 1 or 2, who were 18
years or older, with best-corrected visual acuity
scores between 24 and 78 Early Treatment of
Diabetic Retinopathy Study letters (20/32–20/320
Snellen equivalent), and with the presence of per-
sistent DME which was deﬁned as a CST of .340
mm measured by spectral domain optical coherence
tomography (OCT) despite at least 3 anti-VEGF
injections within the previous 5 months. Fluores-
cein angiography was performed at the baseline
visit to rule out signiﬁcant foveal nonperfusion. Pre-
vious treatment of DME was allowed, and most
subjects had far more than the minimum that this
study required. Exclusion criteria included any in-
travitreal anti-VEGF injection within the previous 4
weeks, intravitreal triamcinolone injection within
the previous 8 weeks, intravitreal dexamethasone
(Ozurdex) within the previous 16 weeks, and laser
photocoagulation of the retina within the previous
16 weeks. Other exclusion criteria included active
iris neovascularization, aphakia, pseudophakia with
anterior chamber intraocular lens, signiﬁcant epire-
tinal membrane or vitreomacular traction that could
contribute to secondary macular edema, active or
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suspected ocular or periocular infections including
most viral diseases of the cornea and conjunctiva
including active epithelial keratitis due to herpes
simplex, herpes zoster, vaccinia, mycobacteria, or
fungi, a known history of intraocular pressure
(IOP) increase because of corticosteroids that would
not be adequately controlled with 2 topical glau-
coma medications, hypersensitivity to any compo-
nent of Avastin or Ozurdex, enrollment in an
investigational drug study within the previous 30
days, and any condition that in the opinion of the
investigator might compromise the results of the
trial or preclude the patient from completing all
study visits. Female patients of childbearing age
were required to have a negative pregnancy test
before enrollment and to use a reliable form of con-
traception throughout the study.
Treatment Groups and Randomization
After providing written consent, eligible subjects
were randomly assigned to one of 2 treatments: 1)
intravitreal bevacizumab (IVB) (Avastin, Genentech,
Inc., South San Fancisco, CA) monotherapy or 2)
intravitreal dexamethasone delayed delivery system
implant (DDS) (Ozurdex) monotherapy (DDS) in a 1:1
ratio (see Figure, Supplemental Digital Content 1,
http://links.lww.com/IAE/A439, which illustrates the
study design). Randomization was achieved by non-
study personnel using computer-generated allocations
and with 2 sets of sealed envelopes (one set for base-
line visual acuity ,65 letters and another set for base-
line visual acuity $65 letters at baseline). For patients
in whom both eyes met the eligibility criteria, the right
eye was randomized to a treatment group and the left
eye was assigned to the other group. The study dura-
tion was 7 months.
Eyes assigned to the IVB group received intravitreal
injection of bevacizumab (Avastin) 1.25 mg in 0.05 mL
at baseline and monthly thereafter if retreatment criteria
were met. If retreatment criteria were not met at any of
the monthly visits, then sham injection was adminis-
tered at those visits. Eyes assigned to the DDS group
received intravitreal injection of the dexamethasone
DDS implant (Ozurdex) 0.7 mg at baseline, Month 3,
and Month 6, and sham injections at Months 1, 2, 4,
and 5. If retreatment criteria were not met at Month 3,
then sham injection was administered at Month 3 and
Ozurdex was then administered at Month 4. If retreat-
ment criteria were not met at Month 6, then sham
injection was administered at Month 6. Ozurdex could
not be administered at an interval of less than 3 months.
Retreatment criteria included either visual acuity
,83 letters or CST $300 mm. Retreatment was with-
held only if visual acuity was$83 letters and CST was
,300 mm. Escape criteria included an increase of CST
by $200 mm from baseline at any of the Months 2
through 6 for either group, which would qualify the
subject for withdrawal from the study at the investi-
gator’s discretion.
Outcomes and Statistical Analysis
Outcomes were analyzed in terms of efﬁcacy and
safety. The primary efﬁcacy measures included
mean change in visual acuity from baseline to Month
7 and mean change in CST from baseline to Month
7. The secondary efﬁcacy measures included mean
number of 10- and 15-letter gainers from baseline to
Month 7, mean time to 10-letter gain, mean change
in visual acuity based on previous number of anti-
VEGF injections, and mean change in total macular
volume from baseline to Month 7. The safety
measures included glaucoma-related outcomes such
as mean change in IOP, number of visits with IOP
exceeding 21 mmHg, number of patients requiring
addition of ocular antihypertensive medications or
laser or incisional glaucoma surgery during the
study, and mean change in OCT retinal nerve ﬁber
layer average thickness. Other safety measures
including cataracts, endophthalmitis, other ocular
serious adverse events, and systemic serious adverse
events were recorded as well.
The baseline characteristics of the cohort, includ-
ing demographics, disease and treatment history, and
functional and morphologic measurements, were
summarized by descriptive statistics. The efﬁcacy
and safety measures were statistically analyzed
using nonparametric tests, including Mann–Whitney
U test and Fisher’s exact t-test, and using an intent-
to-treat approach.
Results
Baseline Characteristics
Between January 29, 2014, and October 15, 2014,
50 eyes of 45 patients (mean age 61 ± 10 years) were
enrolled, with 23 and 27 eyes assigned to the IVB
and DDS groups, respectively. The baseline charac-
teristics of study subjects and enrolled eyes were
similar in both groups as summarized in Table 1.
In particular, average visual acuity, CST, and total
macular volume were equivalent in both groups. The
treatments that the eyes had received before study
enrollment are summarized in Table 2, and were
similar in both groups as well.
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Follow-up
Monthly evaluation, including the 7-month evalua-
tion, was performed in 23 (100%) eyes in the IVB
group and 27 (100%) eyes in the DDS group. None of
the eyes were lost to follow-up in either group. Optical
coherence tomography data were unavailable (or
unable to be recorded) for two eyes (at one visit for
one eye and at three visits for another eye) in the IVB
group and for two eyes (at one visit for each of the two
eyes) in the DDS group. Outcomes were calculated
based on eyes with available data for each of the visits.
Treatments
Twenty-two (96%) eyes in the IVB group met
retreatment criteria at each of the scheduled injection
visits, and received a total of 7 bevacizumab injections
each. One (4%) eye in the IVB group did not meet
retreatment criteria at one of the visits, and received
a total of 6 bevacizumab injections. Nineteen (71%)
eyes in the DDS group met retreatment criteria at each
of the scheduled injection visits and received a total of
3 dexamethasone injections. Eight (29%) eyes in the
DDS group did not meet retreatment criteria at one of
the scheduled visit, and received a total of 2 dexa-
methasone injections each. Number of injections per
eye (mean ± SD) was 7.0 ± 0.2 in the IVB group and
2.7 ± 0.5 in the DDS group (P , 0.001) over 7
months. None of the eyes were withdrawn from the
study at the discretion of the investigator.
Efﬁcacy Measures
The visual outcomes in the 2 groups are summarized
and compared in Table 3. As noted, all visual out-
comes were similar in both groups (see Figure, Sup-
plemental Digital Content 2, http://links.lww.com/
IAE/A440, which graphically illustrates the visual acu-
ity over time). The change in visual acuity over time is
graphically demonstrated in Figure 1. The number of
Table 1. Bevacizumab Versus Dexamethasone Implant for Persistent Diabetic Macular Edema: Baseline Characteristics
Feature
IVB Group, Mean ± SD
(n = 23 Eyes)
DDS Group, Mean ± SD
(n = 27 Eyes) P
Age, yrs 61 ± 9 65 ± 11 0.209
Gender, n (%) 0.571
Male 13 (57) 12 (44)
Female 10 (44) 15 (56)
Race, n (%) 0.614
White 22 (96) 24 (89)
African-American 1 (4) 3 (11)
Diabetes mellitus, n (%) 0.090
Type 1 3 (13) 0 (0)
Type 2 20 (87) 27 (100)
Lens status, n (%) 0.407
Phakic 14 (61) 13 (48)
Pseudophakic 9 (39) 14 (52)
BCVA (ETDRS letters)
(mean Snellen visual acuity)
59 ± 13 (20/63) 59 ± 12 (20/63) 0.770
IOP, mmHg 16 ± 2 15 ± 2 0.619
CST, mm 485 ± 122 458 ± 100 0.508
TMV, mm3 12.0 ± 1.9 11.7 ± 1.9 0.350
BCVA, best-corrected visual acuity; DDS, intravitreal dexamethasone delayed delivery system implant; ETDRS, early treatment diabetic
retinopathy study; TMV, total macular volume.
Table 2. Bevacizumab Versus Dexamethasone Implant for Persistent Diabetic Macular Edema: Summary of Treatments
Before the Study
Feature
IVB Group, Mean ± SD
(n = 23 Eyes)
DDS Group, Mean ± SD
(n = 27 Eyes) P
Number of previous intravitreal anti-VEGF injections 15 ± 11 18 ± 12 0.311
Interval from last intravitreal anti-VEGF injection, wk 6 ± 6 6 ± 4 0.825
Number of previous intravitreal triamcinolone injections 8 ± 6 (n = 11) 9 ± 6 (n = 29) 0.767
Interval from last intravitreal triamcinolone injection, wk 41 ± 19 (n = 11) 89 ± 111 (n = 29) 0.225
Number of previous intravitreal DDS injections 2 ± 1 (n = 3) 2 ± 1 (n = 3) 0.361
Interval from last intravitreal DDS injection, wk 85 ± 46 (n = 3) 81 ± 8 (n = 3) 0.513
DDS, intravitreal dexamethasone delayed delivery system implant; IVB, intravitreal bevacizumab.
BEVACIZUMAB VERSUS DEXAMETHASONE FOR DME  SHAH ET AL 1989
10- and 15- letter gainers and losers is graphically
demonstrated in Figure 2. A trend was noted to sug-
gest greater responsiveness to the dexamethasone
implant compared with bevacizumab for eyes with
greater number of previous anti-VEGF injections,
but this was not statistically signiﬁcant (Figure 3). A
trend was also noted to suggest greater responsiveness
to the dexamethasone implant compared with bevaci-
zumab for eyes with worse baseline visual acuity, but
this was not statistically signiﬁcant (Figure 4).
The anatomical outcomes in the 2 groups are
summarized and compared in Table 4. As noted, mac-
ular thickness and volume outcomes were all superior
in the DDS group compared with the IVB group. The
number (%) of eyes considered “dry” on OCT as per
study criterion of CST ,300 mm was 1 (4%), 0 (0%),
0 (0%), 0 (0%), 2 (9%), 0 (0%), and 0 (0%) in the IVB
group and 10 (37%), 11 (42%), 9 (35%), 11 (41%), 13
(48%), 11 (41%), and 11 (41%) in the DDS group at
monthly visits from Month 1 to Month 7. Central sub-
ﬁeld thickness over time is shown in Figure 5, showing
early reduction of macular thickness on OCT and a sus-
tained deturgescence in the DDS group over the course
of the study, with statistically signiﬁcant difference in
macular thickness at each visit compared with the IVB
group. The macular volume showed a corresponding
signiﬁcant difference in outcomes at each visit (see
Figure, Supplemental Digital Content 3, http://links.
lww.com/A441, which graphically illustrates the total
macular volume over time). Response to treatment as
seen on OCT is illustrated in Figure 6, with the 2 eyes
of the same subject enrolled in the 2 groups.
Safety Measures
No serious systemic safety concerns emerged during
this study. The safety outcomes in the 2 groups are
summarized and compared in Table 5. Regarding
Table 3. Bevacizumab Versus Dexamethasone Implant for Persistent Diabetic Macular Edema: Visual Acuity Outcomes at
Month 7
Feature
IVB Group, Mean ± SD,
(n = 23 Eyes)
DDS Group, Mean ± SD
(n = 27 Eyes) P
Final BCVA (ETDRS letters) (mean Snellen visual acuity) 65 ± 16 (20/50) 64 ± 11 (20/50) 0.619
Change in BCVA (ETDRS letters) +5.6 ± 6.1 +5.8 ± 7.6 0.785
Number of 10-letter gainers, n (%) 6 (26) 9 (33) 0.758
Number of 15-letter gainers, n (%) 3 (13) 4 (15) 1.000
Number of 10-letter losers, n (%) 0 (0) 0 (0) —
Number of 15-letter losers, n (%) 0 (0) 0 (0) —
Mean time to 10-letter gain, mo 3.6 ± 1.9 3.5 ± 1.9 0.880
BCVA, best-corrected visual acuity; DDS, intravitreal dexamethasone delayed delivery system implant; ETDRS, Early Treatment
Diabetic Retinopathy Study; IVB, intravitreal bevacizumab.
Fig. 1. Change in visual acuity.
The graph illustrates the change
in visual acuity from baseline at
each visit, comparing bev-
acizumab with the dexametha-
sone implant for persistent DME.
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glaucoma-related outcomes, signiﬁcantly greater pro-
portion of patients in the DDS group had an IOP ele-
vation and required glaucoma agents for IOP control;
however, none of the eyes required laser or incisional
surgery for glaucoma in either group. In the IVB
group, none of the eyes had IOP .21 mmHg at any
visit. In the DDS group, the number of eyes with IOP
exceeding 21, 23, 25, and 30 mmHg at each of the
monthly visits is summarized in Table 6. The absolute
and the change in peripapillary retinal nerve ﬁber layer
thickness were similar in both groups at the end of the
study. The IOP trend over time in the 2 groups is
shown in Figure 7. The number of ocular antihyper-
tensive medications required for IOP control in the
DDS group was signiﬁcantly higher than that in the
IVB group (see Figure, Supplemental Digital Con-
tent 4, http://links.lww.com/IAE/A442, which graphi-
cally illustrates the number of ocular antihypertensive
required over time). Most eyes requiring ocular anti-
hypertensive treatment were started on a dorzolamide/
timolol combination, whereas a few eyes were started
on a single agent (brimonidine), as per physician dis-
cretion. Of those eyes that were already on either of
those therapy, a new agent was required to be added in
Fig. 2. Ten- and 15-letter gainers
and losers. The graph illustrates
the percentage of eyes with 10-
and 15-letter gains, and 10- and
15-letter losses at Month 7, com-
paring bevacizumab with dexa-
methasone implant for persistent
DME.
Fig. 3. Change in visual acuity
and number of previous anti-
VEGF injections. The graph il-
lustrates change in visual acuity
from baseline to Month 7, based
on the number of previous anti-
VEGF injections before study
enrollment. It shows a non-
signiﬁcant trend toward greater
visual acuity gain with dexa-
methasone in eyes with greater
number of previous anti-VEGF
injections.
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0 (0%) eyes in the IVB group, and 5 (19%) eyes in the
DDS group (2 eyes at Month 2, 2 eyes at Month 4, and
one eye at Month 6). Cataract progression was noted
in a higher proportion of DDS-group eyes, but this
difference was not statistically signiﬁcant during the
short duration of the study. The speciﬁc ocular and
systemic serious adverse events are summarized in
Table 5, and occurred at a similar rate in both groups.
Discussion
While the pathophysiology of DME involves excess
VEGF production as one of the key factors, it involves
several other mechanisms as well. Anti-VEGF agents
block and directly inhibit VEGF. Corticosteroid
agents, however, have several mechanisms of action,
including decrease in VEGF production and release,
decrease in leukocyte migration, decrease in several
proinﬂammatory cytokines and prostaglandins, down-
regulation of ICAM-1 expression, and also effect on
retinal endothelial cells to enhance the barrier function
of vascular tight junctions (antipermeability effect).13–16
With multiple targets of action, corticosteroids may the-
oretically offer better control in persistent DME.
Various corticosteroid agents that have been used
for intravitreal use include triamcinolone acetonide,
ﬂuocinolone acetonide implants, and dexamethasone
implants. DRCR protocol I showed that triamcino-
lone plus laser achieved similar visual gain as
ranibizumab plus prompt or deferred laser groups
in the pseudophakic subgroup at one year.3 The
FAME study of intravitreal ﬂuocinolone acetonide
(Iluvien) in patients with refractory DME showed
an improvement of at least 15 letters in 29% of pa-
tients receiving the 0.2 mg/day insert; beneﬁts sus-
tained for over 3 years.17 Dexamethasone is 6 times
more potent than triamcinolone acetonide but has
a shorter half-life in vitreous. The dexamethasone
implant (Ozurdex) is speciﬁcally designed for intra-
ocular use with polylactic-co-glycolic acid copoly-
mer packaging for prolonged and sustained release
over several months. The MEAD study found that
dexamethasone implants at both 0.7-mg and 0.35-
mg doses met the primary efﬁcacy endpoint of sig-
niﬁcantly greater proportion of eyes with .15 letter
best-corrected visual acuity improvement (22% and
18%) at the end of 3 years compared with sham
(12%).18 The PLACID study showed that there were
signiﬁcantly greater 10-line gainers (32% vs. 17%)
Fig. 4. Change in visual acuity
and baseline visual acuity. The
graph illustrates change in visual
acuity from baseline to Month 7,
based on the baseline visual acu-
ity. It shows a nonsigniﬁcant
trend toward greater visual acuity
gain with dexamethasone in eyes
with poorer baseline visual acuity.
Table 4. Bevacizumab Versus Dexamethasone Implant for Persistent Diabetic Macular Edema: Anatomical Outcomes at
Month 7
Feature IVB Group, Mean ± SD (n = 23 Eyes) DDS Group, Mean ± SD (n = 27 Eyes) P
Final CST, mm 471 ± 157 336 ± 89 0.001
Change in CST, mm 213 ± 105 2122 ± 120 0.001
Final TMV, mm3 12.0 ± 2.4 10.7 ± 1.4 0.027
Change in TMV, mm3 20.5 ± 2.8 21.0 ± 1.4 0.007
DDS, intravitreal dexamethasone delayed delivery system implant; IVB, intravitreal bevacizumab; TMV, total macular volume.
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up to 9 months in the dexamethasone plus laser
group compared with the sham plus laser group for
DME, but the difference was not signiﬁcant at 12
months.19
The duration of efﬁcacy of dexamethasone was
originally intended to be 6 months; however, it has
been shown in several studies that, at least in persistent
DME, its efﬁcacy lasts approximately 3 months.12,20,21
Pacella et al demonstrated in their 6-month prospective
study of eyes with persistent DME after multiple pre-
vious therapies, including anti-VEGF agents, that the
effect of a single Ozurdex injection has clinical efﬁ-
cacy lasting approximately 3 months to 4 months, with
a statistically signiﬁcant Early Treatment of Diabetic
Retinopathy Study letter gain compared with baseline
until Month 4 and a statistically signiﬁcant CST reduc-
tion compared with baseline until Month 3.20 Totan
et al21 conducted a similar 6-month prospective study
and found the signiﬁcant visual acuity gain lasting
until Month 3 and a signiﬁcant CST reduction lasting
Fig. 5. Macular thickness. The
graph illustrates the CST mea-
sured using OCT from baseline to
Month 7, comparing bev-
acizumab with dexamethasone
implant for persistent DME.
Fig. 6. Macular OCT. Illustration
of two eyes of the same patient
with similar macular CST and
total macular volume at baseline,
with left eye randomized to bev-
acizumab and right eye to dexa-
methasone implant. At Month 7,
the dexamethasone-arm eye had
signiﬁcantly better anatomical
resolution of macular edema.
Visual acuity gain is also speci-
ﬁed. VA, visual acuity; TMV,
Total macular volume.
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until Month 6, after a single Ozurdex injection in per-
sistent DME deﬁned similarly. Our previous study
comparing a combination of dexamethasone implants
and bevacizumab with bevacizumab alone showed
a similar period of efﬁcacy of 3 months as well, with
edema returning to baseline by Month 4.12 In this
study, a q3month dexamethasone implant was able
to sustain the macular thickness control without any
signiﬁcant ﬂuctuations over time (Figure 5).
Our present study has 2 additional ﬁndings—a trend
toward greater visual acuity gain in eyes that have
received a greater number of anti-VEGF injections
previously and a trend toward greater visual acuity
gain in eyes with poorer (,20/50) baseline visual acu-
ity. Although these trends are not statistically signiﬁ-
cant, they require further investigation because this
study was not powered to test these differences.
It should be noted that cross-comparison between
various studies evaluating persistent or refractory DME
is challenging because of variations in deﬁnitions,
enrollment criteria, duration of study, and types and
frequency of treatments, among other factors. BEV-
ORDEX was a randomized controlled trial that com-
pared dexamethasone implants with bevacizumab in the
treatment of center-involving DME unresponsive to
macular laser and found that visual acuity gain was
statistically similar (+5.6 vs. +8.9), central macular
thickness reduction was signiﬁcantly greater (2187
vs. 2122), and the number of injections required was
signiﬁcantly lower (2.7 vs. 8.6 over 12 months).22
However, more dexamethasone-treated eyes lost vision
than bevacizumab-treated eyes, owing to the increased
rate of cataract formation.22 The visual and anatomical
outcomes of our study are in line with the BEVORDEX
study, and the rate of cataract formation in our study
was not signiﬁcantly different between the two groups,
most likely owing to the shorter follow-up.
An important consideration against using intra-
vitreal corticosteroid agents includes their potential
for IOP elevation and glaucoma. One of the
Table 5. Bevacizumab Versus Dexamethasone Implant for Persistent Diabetic Macular Edema: Safety Outcomes at
Month 7
Feature
IVB Group,
Mean ± SD
(n = 23 Eyes)
DDS Group,
Mean ± SD
(n = 27 Eyes) P
Final IOP, mmHg 15 ± 2 17 ± 3 0.096
Change in IOP, mmHg 20.7 ± 2.5 +1.1 ± 3.9 0.049
Number of visits where IOP .21 mmHg 0 ± 0 1.3 ± 1.5 ,0.001
Number of visits at which ocular antihypertensive
medications were required to be used
0.3 ± 1.3 2.4 ± 2.8 0.002
Number of patients requiring addition of ocular
antihypertensive medications at any of the
visits during the study
1 (5) 13 (50) 0.001
Number of patients requiring laser or incisional
glaucoma surgery during the study
0 (0) 0 (0) —
IOP .21 mmHg at least one visit, n (%) 0 (0) 14 (52) ,0.001
Final RNFL, mm 88 ± 12 91 ± 11 0.417
Change in RNFL, mm 21.2 ± 5.2 23.3 ± 6.5 0.500
Cataract, n (%) 4 (17) 7 (26) 0.515
Endophthalmitis, n (%) 0 (0) 0 (0) —
Ocular SAEs*, n (%) 3 (13) 2 (7) 0.651
Systemic SAEs†, n (%) 4 (17) 1 (4) 0.167
*Ocular SAEs included—IVB group: vitreous hemorrhage (n = 2) and cranial nerve VI palsy (n = 1); DDS group: vitreous hemorrhage (n = 1)
and choroidal detachment (n = 1).
†Systemic SAEs included—IVB group: bradycardia (n = 1), pneumonia (n = 1), pyelonephritis (n = 1), and colon cancer (n = 1); DDS
group: congestive heart failure (n = 1).
DDS, intravitreal dexamethasone delayed delivery system implant; IVB, intravitreal bevacizumab; RNFL, retinal nerve ﬁber layer; SAEs,
serious adverse events.
Table 6. Number of Eyes With IOP Elevation at Monthly Visits in the Dexamethasone Implant Group
IOP, mmHg
Month 1,
n (%)
Month 2,
n (%)
Month 3,
n (%)
Month 4,
n (%)
Month 5,
n (%)
Month 6,
n (%)
Month 7,
n (%)
.21 3 (11) 10 (37) 2 (7) 3 (11) 8 (30) 5 (19) 2 (7)
.23 3 (11) 5 (19) 0 (0) 3 (11) 4 (15) 3 (11) 1 (4)
.25 3 (11) 3 (11) 0 (0) 1 (4) 1 (4) 1 (4) 1 (4)
.30 1 (4) 1 (4) 0 (0) 1 (4) 1 (4) 0 (0) 0 (0)
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strengths of our study is speciﬁc analyses of
glaucoma-related outcomes. Intraocular pressure
elevation occurred in a signiﬁcantly greater number
of eyes in the dexamethasone arm and a correspond-
ingly greater number of ocular antihypertensive
agents were required in this group. However, optic
nerve OCT failed to show any signiﬁcant difference
in absolute or relative change in retinal nerve ﬁber
layer thickness at Month 7. Also, none of the eyes
required laser or surgical glaucoma treatments. It is
noteworthy that although the dexamethasone-
implant group patients required signiﬁcantly fewer
injections than the bevacizumab group, they still
needed follow-up every 4 weeks to 6 weeks for IOP
monitoring and management, thereby not translating
into fewer patient visits. Second, although a detailed
cost-effectiveness analysis is beyond the scope of
our study, another consideration against dexameth-
asone implant use is its signiﬁcantly higher cost
compared with bevacizumab, despite fewer injec-
tions. However, dexamethasone implants would be
less expensive than using either ranibizumab (Lu-
centis, Genentech, Inc., South San Fancisco, CA) or
aﬂibercept (Eylea, Regeneron Pharmaceuticals, Inc.,
Tarrytown, NY), per label.
Some of the limitations of our study include the
short duration of follow-up and the small sample size.
Future studies on persistent DME with longer follow-
up and detailed analysis of glaucoma-related outcomes
would be helpful. In addition, the effect of switching
over to bevacizumab after an initial good response to
dexamethasone for patients with signiﬁcant IOP
elevation/steroid response would be helpful as well.
Moreover, our study suggests a trend indicating that
earlier treatment of chronic macular edema may result
in a better ﬁnal visual acuity. Thus, the use of
alternative treatments to anti-VEGF agents alone
should likely be considered earlier in the treatment
process. Finally, the trends suggested regarding the
merits of dexamethasone, especially with early treat-
ment, is worthy of further analyses.
Key words: bevacizumab, dexamethasone, diabetic
macular edema, optical coherence tomography, sus-
tained release implant, vascular endothelial growth
factor.
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